Literature DB >> 11606883

Coincidence detection FDG PET in the management of oncological patients: attenuation correction versus non-attenuation correction.

W L Chan1, J Freund, N A Pocock, E Szeto, F Chan, B J Sorensen, B McBride.   

Abstract

The aim of this study was to determine if attenuation correction (AC) in a dual-head, coincidence, positron emission tomography imaging system (Co-PET) improved image quality, lesion detection, patient staging and management of various malignant neoplasms, compared to non-attenuation corrected (NAC) images. Thirty patients with known or suspected malignant neoplasms underwent fluorodeoxyglucose (FDG) Co-PET, which was correlated with histopathology, computed tomography (CT) and other conventional imaging modalities and clinical follow-up. The number and location of FDG avid lesions detected on the AC images and NAC Co-PET images were blindly assessed by two independent observers. Semi-quantitative grading of image clarity and lesion-to-background quality was performed. This revealed markedly improved image clarity and lesion-to-background quality in the AC versus NAC Co-PET images. AC Co-PET was statistically superior to NAC Co-PET in relation to lesion detection (P<0.01) and tumour staging (P<0.01). NAC Co-PET demonstrated 51 of the 65 lesions (78%) detected by AC Co-PET. AC Co-PET altered tumour staging in five additional patients (16%) compared to NAC Co-PET. Management was altered in two of these five patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606883     DOI: 10.1097/00006231-200111000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  1 in total

Review 1.  Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in oncology: a systematic review.

Authors:  Urvi Joshi; Pieter G H M Raijmakers; Ingrid I Riphagen; Gerrit J J Teule; Arthur van Lingen; Otto S Hoekstra
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.488

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.